JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG, and the Institute for Medical Immunology at the Charité in Berlin recently announced a collaborative agreement to develop serological peptide markers for the differential diagnosis of chronic fatigue syndrome (CFS)
Although we are believers in genomics, we suspect that it will take the conventional 20 years or so between investment in research and commercial exploitation. We also feel that application of genomics to healthcare delivery will take place by a large number of small steps, and not as a big bang. In short, a genome’s got to know its limitations.
Too often, the industry’s hands appear to be tied when it comes to providing target markets with information, as regulatory agencies and advertising counsels argue that consumers aren’t capable of digesting this information. I think we’re not giving today’s consumers enough credit.
If you’re in a position to create treatments for cancer, what’s the silver bullet for you? Is it creating a safe and effective blockbuster drug that brings in the revenue your company needs to continue work on future drugs? Is it an altruistic quest for a cure?